CVRx, Inc. (CVRX)
- Previous Close
5.29 - Open
5.44 - Bid 6.13 x 100
- Ask 6.23 x 100
- Day's Range
5.36 - 6.23 - 52 Week Range
4.30 - 18.55 - Volume
959,426 - Avg. Volume
404,181 - Market Cap (intraday)
161.389M - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
-- - EPS (TTM)
-2.50 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
www.cvrx.comRecent News: CVRX
View More
Performance Overview: CVRX
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVRX
View MoreValuation Measures
Market Cap
137.92M
Enterprise Value
85.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.38
Price/Book (mrq)
1.99
Enterprise Value/Revenue
1.62
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-97.49%
Return on Assets (ttm)
-26.88%
Return on Equity (ttm)
-76.01%
Revenue (ttm)
52.87M
Net Income Avi to Common (ttm)
-51.55M
Diluted EPS (ttm)
-2.50
Balance Sheet and Cash Flow
Total Cash (mrq)
102.67M
Total Debt/Equity (mrq)
72.70%
Levered Free Cash Flow (ttm)
-25.25M